How One Rogue Scientist Could Sink Global Gene Therapy Progress
Executive Summary
Amid a global uproar denouncing a Chinese scientist’s work to deliver gene-edited twin babies, worries emerge that other valuable future research in the area could be put on hold, effectively crippling industry experts and researchers.
You may also be interested in...
Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Nearly 9% FY 2019 Increase For FDA In Shutdown-Averting Appropriations Bill
Consolidated Appropriations Act gives FDA $5.58bn overall, 8.7% more than allocated in FY 2018. FDA received $268.8m in additional budget authority and $178.3m in additional user fee funds. FY 2019 funding would have lapsed Feb. 16 and another government shutdown would have started if President Trump didn't sign the bill on Feb. 15.
US FDA Wins Big In Shutdown-Averting Approps Bill
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
